Indoxyl sulfate, a uremic toxin, is biotransformed from indoxyl-β-d-glucoside (indican) in rats

Toxicon

Volumn 52, Issue 3, 2008, Pages 440-444

  Hou, Yu Chi ^a   Tsai, Shang Yuan ^a   Chan, Shu Ling ^a   Yang, Shih Ying ^a   Chao, Pei Dawn Lee ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Indican; Indoxyl sulfate; Indoxyl d glucoside; Metabolism; Pharmacokinetics; Uremic toxin

Indexed keywords

INDICAN; UREMIC TOXIN;

ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; BLOOD SAMPLING; CHEMICAL STRUCTURE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLISM; NONHUMAN; PRIORITY JOURNAL; PUNCTURE; RAT; TOXICOKINETICS;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSIDES; INDICAN; INJECTIONS, INTRAVENOUS; MALE; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

CLERODENDRUM; GLEHNIA LITTORALIS; ISATIS TINCTORIA; POLYGONUM TINCTORIUM; RATTUS;

EID: 50549083675     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2008.06.014     Document Type: Article

References (22)

1. Banoglu E., Jha G.G., and King R.S. Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet 26 (2001) 235-240
2. Bueschkens D.H., and Stiles M.E. Escherichia coli variants for gas and indole production at elevated incubation temperatures. Appl. Environ. Microbiol. 48 (1984) 601-605
3. Chao P.D.L., Hsiu S.L., and Hou Y.C. Flavonoids in herbs: biological fates and potential interactions with xenobiotics. J. Food Drug Anal. 10 (2002) 219-228
4. Choo M.K., Park E.K., Yoon H.K., and Kim D.H. Antithrombotic and antiallergic activities of daidzein, a metabolite of puerarin and daidzin produced by human intestinal microflora. Biol. Pharm. Bull. 25 (2002) 1328-1332
5. Day A.J., Gee J.M., DuPont M.S., Johnson I.T., and Williamson G. Absorption of quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. Biochem. Pharmacol. 65 (2003) 1199-1206
6. Deguchi T., Nakamura M., Tsutsumi Y., Suenaga A., and Otagiri M. Pharmacokinetics and tissue distribution of uraemic indoxyl sulphate in rats. Biopharm. Drug Dispos. 24 (2003) 345-355
7. Dou L., Jourde-Chiche N., Faure V., Cerini C., Berland Y., Dignat-George F., and Brunet P. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J. Thromb. Haemost. 5 (2007) 1302-1308
8. Enomoto A., Takeda M., Tojo A., Sekine T., Cha S.H., Khamdang S., Takayama F., Aoyama I., Nakamura S., Endou H., and Niwa T. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J. Am. Soc. Nephrol. 13 (2002) 1711-1720
9. Hollman P.C., de Vries J.H., van Leeuwen S.D., Mengelers M.J., and Katan M.B. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr. 62 (1995) 1276-1282
10. Hou Y.C., Chao P.D.L., Ho H.J., Wen C.C., and Hsiu S.L. Profound difference of pharmacokinetics between morin and its isomer quercetin in rats. J. Pharm. Pharmacol. 55 (2003) 199-203
11. Hsiu S.L., Huang T.Y., Hou Y.C., Chin D.H., and Chao P.D.L. Comparison of metabolic pharmacokinetics of naringin and naringenin in rabbits. Life Sci. 70 (2002) 1481-1489
12. Lai M.Y., Hsiu S.L., Tsai S.Y., Hou Y.C., and Chao P.D.L. Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats. J. Pharm. Pharmacol. 55 (2003) 205-209
13. Lim C.F., Bernard B.F., and de Jong M. A furan fatty acid and indoxyl sulphate are the putative inhibitors of thyroxine hepatocyte transport in uraemia. J. Clin. Endocrinol. Metab. 76 (1993) 318-324
14. Lin Y.T., Chang P.H., Wen K.C., Yu C.P., Chao P.D.L., and Hou Y.C. Presystemic metabolism of anthraquinone polyphenols in rhubarb. Mid. Taiwan J. Med. 9 (2004) 87-95
15. Németh K., Plumb G.W., Berrin J.G., Juge N., Jacob R., Naim H.Y., Williamson G., Swallow D.M., and Kroon P.A. Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur. J. Nutr. 42 (2003) 29-42
16. Niwa T. Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin. Nephrol. 16 (1996) 167-182
17. Niwa T., and Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J. Lab. Clin. Med. 124 (1994) 96-104
18. Niwa T., Ise M., and Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am. J. Nephrol. 14 (1994) 207-212
19. Niwa T., Aoyama I., Takayama F., Tsukushi S., Miyazaki T., Owada A., and Shiigai T. Urinary indoxyl sulfate is a clinical factor that affects the progression of renal failure. Miner. Electrolyte. Metab. 25 (1999) 118-122
20. Sakai T., Yamasaki K., Sako T., Kragh-Hansen U., Suenaga A., and Otagiri M. Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm. Res. 18 (2001) 520-524
21. Taki K., Tsuruta Y., and Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am. J. Nephrol. 27 (2007) 30-35
22. Tsutsumi Y., Maruyama T., Takadate A., Shimada H., and Otagiri M. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron 85 (2000) 60-64